Why the optimal requirement for Vitamin D3 is probably much higher than what is officially recommended for adults

Journal of Steroid Biochemistry and Molecular Biology

Volumn 89-90, Issue , 2004, Pages 575-579

  Vieth, Reinhold ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Calcium; Environment; Evolution; Hypertension; Skin; Vitamin D3

Indexed keywords

25 HYDROXYVITAMIN D; CALCIUM; COLECALCIFEROL; INSULIN; PARATHYROID HORMONE; VITAMIN D;

AUTOIMMUNE DISEASE; BLOOD PRESSURE REGULATION; BONE DENSITY; BONE MINERAL; CALCIUM ABSORPTION; CANCER PREVENTION; CLINICAL TRIAL; CONFERENCE PAPER; CORRELATION ANALYSIS; DRUG EFFECT; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MULTIPLE SCLEROSIS; OSTEOPOROSIS; RANDOMIZATION;

ADULT; AUTOIMMUNE DISEASES; BLOOD PRESSURE; CHOLECALCIFEROL; FRACTURES, BONE; HUMANS; NEOPLASMS; NUTRITION POLICY;

PRIMATES;

EID: 3042636277     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2004.03.038     Document Type: Conference Paper

References (62)

1. Blumberg R.W., Forbes G.B., Fraser D., et al. The prophylactic requirement and the toxicity of Vitamin D. Pediatrics. 31:1963;512-525
2. Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am. J. Clin. Nutr. 69:1999;842-856
3. Vieth R., Fraser D. Vitamin D insufficiency: no recommended dietary allowance exists for this nutrient. CMAJ. 166:2002;1541-1542
4. R. Vieth, Effects of Vitamin D on bone and natural selection of skin color: how much Vitamin D nutrition are we talking about? in: S.C. Agarwal, S.D. Stout (Eds.), Bone Loss and Osteoporosis in Past Populations: an Anthropological Perspective, Kluwer Academic Plenum, 2004.
5. Vieth R., Kessler M.J., Pritzker K.P. Serum concentrations of Vitamin D metabolites in Cayo Santiago rhesus macaques. J. Med. Primatol. 16:1987;349-357
6. 2. J. Clin. Endocrinol. Metab. 69:1989;1282-1289
7. Adams J.E., Gacad M.A., Baker A.J., Rude R.K. Serum concentrations of 1, 25-dihydroxyvitamin D3 in Platyrrhini and Cathrrhini: a phylogenetic appraisal. Am. J. Primatol. 9:1985;219-224
8. Kewenig S., Schneider T., Hohloch K., et al. Rapid mucosal CD4(+) T-cell depletion and enteropathy in simian immunodeficiency virus-infected rhesus macaques. Gastroenterology. 116:1999;1115-1123
9. Gacad M.A., Adams J.S. Specificity of steroid binding in New World primate B95-8 cells with a Vitamin D-resistant phenotype. Endocrinology. 131:1992;2581-2587
10. Vieth R., Chan P.C., MacFarlane G.D. Efficacy and safety of Vitamin D(3) intake exceeding the lowest observed adverse effect level. Am. J. Clin. Nutr. 73:2001;288-294
11. Vieth R., Fraser D., Kooh S.W. Low dietary calcium reduces 25-hydroxycholecalciferol in plasma of rats. J. Nutr. 117:1987;914-918
12. Vieth R., Milojevic S., Peltekova V. Improved cholecalciferol nutrition in rats is noncalcemic, suppresses parathyroid hormone and increases responsiveness to 1, 25-dihydroxycholecalciferol. J. Nutr. 130:2000;578-584
13. Rostand S.G. Ultraviolet light may contribute to geographic and racial blood pressure differences. Hypertension. 30:1997;150-156
14. Freedman D.M., Dosemeci M., McGlynn K. Sunlight and mortality from breast, ovarian, colon, prostate, and non-melanoma skin cancer: a composite death certificate based case-control study. Occup. Environ. Med. 59:2002;257-262
15. Grant W.B., Garland C.F. Evidence supporting the role of Vitamin D in reducing the risk of cancer. J. Intern. Med. 252:2002;178-179
16. T.C. Chen, M.F. Holick, B.L. Lokeshwar, K.L. Burnstein, G.G. Schwartz, Evaluation of Vitamin D analogs as therapeutic agents for prostate cancer, Recent Results Cancer Res. 164 (2003) 273-88, 273-88.
17. Schwartz G.G. Multiple sclerosis and prostate cancer: what do their similar geographies suggest? Neuroepidemiology. 11:1992;244-254
18. Hayes C.E. Vitamin D: a natural inhibitor of multiple sclerosis. Proc. Nutr. Soc. 59:2000;531-535
19. van Der Mei I., Ponsonby A.L., Dwyer T., et al. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. BMJ. 327:2003;316
20. Hypponen E., Laara E., Reunanen A., Jarvelin M.R., Virtanen S.M. Intake of Vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet. 358:2001;1500-1503
21. Al Allaf A.W., Mole P.A., Paterson C.R., Pullar T. Bone health in patients with fibromyalgia. Rheumatology (Oxford). 42:2003;1-5
22. Lind L., Hanni A., Lithell H., Hvarfner A., Sorensen O.H., Ljunghall S. Vitamin D is related to blood pressure and other cardiovascular risk factors in middle-aged men. Am. J. Hypertens. 8:1995;894-901
23. Boucher B.J. Inadequate Vitamin D status: does it contribute to the disorders comprising syndrome 'X'? Br. J. Nutr. 79:1998;315-327
24. Zehnder D., Bland R., Williams M.C., et al. Extrarenal expression of 25-hydroxyvitamin D(3)-1alpha-hydroxylase. J. Clin. Endocrinol. Metab. 86:2001;888-894
25. Tangpricha V., Flanagan J.N., Whitlatch L.W., et al. 25-Hydroxyvitamin D-1alpha-hydroxylase in normal and malignant colon tissue. Lancet. 357:2001;1673-1674
26. H.S. Cross, E. Kallay, H. Farhan, T. Weiland, T. Manhardt, Regulation of extrarenal Vitamin D metabolism as a tool for colon and prostate cancer prevention, Recent Results Cancer Res. 164 (2003) 413-25, 413-25.
27. 3. Cancer Epidemiol. Biomarkers. Prev. 7:1998;391-395
28. Segersten U., Correa P., Hewison M., et al. 25-Hydroxyvitamin D(3)-1alpha-hydroxylase expression in normal and pathological parathyroid glands. J. Clin. Endocrinol. Metab. 87:2002;2967-2972
29. Lehmann B., Genehr T., Knuschke P., Pietzsch J., Meurer M. UVB-induced conversion of 7-dehydrocholesterol to 1alpha, 25-dihydroxyvitamin D3 in an in vitro human skin equivalent model. J. Invest Dermatol. 117:2001;1179-1185
30. Barreto A.M., Schwartz G.G., Woodruff R., Cramer S.D. 25-Hydroxyvitamin D3, the prohormone of 1, 25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells. Cancer Epidemiol. Biomarkers Prev. 9:2000;265-270
31. Holt P.R., Arber N., Halmos B., et al. Colonic epithelial cell proliferation decreases with increasing levels of serum 25-hydroxy Vitamin D. Cancer Epidemiol. Biomarkers Prev. 11:2002;113-119
32. Hsu J.Y., Feldman D., McNeal J.E., Peehl D.M. Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Res. 61:2001;2852-2856
33. Vieth R., Fraser D. Kinetic behavior of 25-hydroxyvitamin D-1-hydroxylase and -24-hydroxylase in rat kidney mitochondria. J. Biol. Chem. 254:1979;12455-12460
34. Vieth R., McCarten K., Norwich K.H. Role of 25-hydroxyvitamin D3 dose in determining rat 1, 25-dihydroxyvitamin D3 production. Am. J. Physiol. 258:1990;E780-E789
35. Vieth R., Ladak Y., Walfish P.G. Age-related changes in the 25-hydroxyvitamin D versus parathyroid hormone relationship suggest a different reason why older adults require more vitamin D. J. Clin. Endocrinol. Metab. 88:2003;185-191
36. Munro I. Derivation of tolerable upper intake levels of nutrients. Am. J. Clin. Nutr. 74:2001;865-867
37. Health & Consumer Protection Directorate-General. Opinion of the Scientific Committee on Food on the Tolerable Upper Intake Level of Vitamin D. EUROPEAN COMMISSION. http://europa.eu.int/comm/food/fs/sc/scf/out157_en.pdf - Accessed August 11, 2003. 2002. Brussels, Belgium. 1-10-0030.
38. Heaney R.P., Davies K.M., Chen T.C., Holick M.F., Barger-Lux M.J. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am. J. Clin. Nutr. 77:2003;204-210
39. Vieth R. Tolerable upper intake level of Vitamin D: Reply to J Hathcock and I Munro. Am. J. Clin. Nutr. 74:2001;866-867
40. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. Dietary Reference Intakes: Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. National Academy Press, 1997.
41. Lips P., Graafmans W.C., Ooms M.E., Bezemer P.D., Bouter L.M. Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial. Ann. Intern. Med. 124:1996;400-406
42. Meyer H.E., Smedshaug G.B., Kvaavik E., Falch J.A., Tverdal A., Pedersen J.I. Can Vitamin D supplementation reduce the risk of fracture in the elderly? A randomized controlled trial. J. Bone Miner. Res. 17:2002;709-7015
43. 3 and calcium to prevent hip fractures in the elderly women. N. Engl. J. Med. 327:1992;1637-1642
44. Dawson-Hughes B., Harris S.S., Krall E.A., Dallal G.E. Effect of calcium and Vitamin D supplementation on bone density in men and women 65 years of age or older. N. Engl. J. Med. 337:1997;670-676
45. 3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporos. Int. 13:2002;257-264
46. 3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ. 326:2003;469-475
47. Lips P. Prevention of hip fractures: drug therapy. Bone. 18:1996;159S-163S
48. Heikinheimo R.J., Inkovaara J.A., Harju E.J., et al. Annual injection of Vitamin D and fractures of aged bones. Calcif. Tissue Int. 51:1992;105-110
49. Pfeifer M., Begerow B., Minne H.W., Abrams C., Nachtigall D., Hansen C. Effects of a short-term Vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. J. Bone Miner. Res. 15:2000;1113-1118
50. Bischoff H.A., Stahelin H.B., Dick W., et al. Effects of Vitamin D and calcium supplementation on falls: a randomized controlled trial. J. Bone Miner. Res. 18:2003;343-351
51. Dhesi J.K., Bearne L.M., Moniz C., et al. Neuromuscular and psychomotor function in elderly subjects who fall and the relationship with Vitamin D status. J. Bone Miner. Res. 17:2002;891-897
52. Devine A., Wilson S.G., Dick I.M., Prince R.L. Effects of Vitamin D metabolites on intestinal calcium absorption and bone turnover in elderly women. Am. J. Clin. Nutr. 75:2002;283-288
53. Heaney R.P., Dowell M.S., Hale C.A., Bendich A. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J. Am. Coll. Nutr. 22:2003;142-146
54. Heaney R.P., Barger-Lux M.J., Dowell M.S., Chen T.C., Holick M.F. Calcium absorptive effects of Vitamin D and its major metabolites [In Process Citation]. J. Clin. Endocrinol. Metab. 82:1997;4111-4116
55. H.A. Bishoff, T. Dietrich, J.E. Orav, B. Dawson-Hughes, Positive association between 25-hydroxyvitamin D levels andbone mineral density: a population-based study of younger and older US adults, in: Proceedings of the 5th International Symposium on Nutritional Aspects of Osteoporosis, Lausanne, Switzerland, May14-17, 2003; 2003 Presentation 20 (Abstract).
56. Health & Consumer Protection Directorate-General. Opinion of the Scientific Committee on Food on the Revision of Reference Values for Nutrition Labelling D. EUROPEAN COMMISSION. http://europa.eu.int/comm/food/fs/sc/scf/ out157_en.pdf - Accessed August 11, 2003, Brussels, Belgium, Accessed August 11, 2003. 8-11-0030.
57. Gloth F.M. III, Tobin J.D., Sherman S.S., Hollis B.W. Is the recommended daily allowance for Vitamin D too low for the homebound elderly? J. Am. Geriatr. Soc. 39:1991;137-141
58. Glerup H., Mikkelsen K., Poulsen L., et al. Hypovitaminosis D myopathy without biochemical signs of osteomalacic bone involvement. Calcif. Tissue Int. 66:2000;419-424
59. Lehtonen-Veromaa M., Mottonen T., Irjala K., et al. Vitamin D intake is low and hypovitaminosis D common in healthy 9- to 15-year old Finnish girls. Eur. J. Clin. Nutr. 53:1999;746-751
60. Vieth R., Cole D.E., Hawker G.A., Trang H.M., Rubin L.A. Wintertime Vitamin D insufficiency is common in young Canadian women, and their Vitamin D intake does not prevent it. Eur. J. Clin. Nutr. 55:2001;1091-1097
61. Brown J.P., Josse R.G. Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ. 167:2002;S1-S34
62. B. Dawson-Hughes, P. Lips, M. Holick, R. Heaney, P. Meunier, R. Vieth, Vitamin D round table, in: B. Dawson-Hughes, R. Heaney, P. Burckhardt (Eds.), Nutritional Aspects of Osteoporosis, Academic Press, New York, 2004.